Hamdani, Nazha

Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension

van Heerebeek, L., Hamdani, N., Handoko, M. L., Falcao-Pires, I., Musters, R. J., Kupreishvili, K., Ijsselmuiden, A. J. J., Schalkwijk, C. G., Bronzwaer, J. G. F., Diamant, M., et al. (2008) · Circulation

Cardiovascular Function and Risk FactorsCardiac Fibrosis and Remodeling

Cited by 723

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

Lee, D. I., Zhu, G., Sasaki, T., Cho, G.-S., Hamdani, N., Holewinski, R., Jo, S.-H., Danner, T., Zhang, M., Rainer, P. P., et al. (2015) · Nature

Phosphodiesterase function and regulationCardiovascular Function and Risk Factors

Cited by 353

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation

Kolijn, D., Pabel, S., Tian, Y., Lódi, M., Herwig, M., Carrizzo, A., Zhazykbayeva, S., Kovács, Á., Fülöp, G. Á., Falcão-Pires, I., et al. (2021) · Cardiovascular Research

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 323

Empagliflozin directly improves diastolic function in human heart failure

Pabel, S., Wagner, S., Bollenberg, H., Bengel, P., Kovács, Á., Schach, C., Tirilomis, P., Mustroph, J., Renner, A., Gummert, J., et al. (2018) · European Journal of Heart Failure

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 224